Tanaka Capital Management Inc. Invests $914,000 in BeyondSpring Inc. (BYSI) Stock
Tanaka Capital Management Inc. acquired a new position in shares of BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring comprises 2.1% of Tanaka Capital Management Inc.’s holdings, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring at the end of the most recent quarter.
A number of research analysts recently commented on the company. Maxim Group assumed coverage on BeyondSpring in a research note on Tuesday, August 22nd. They set a “buy” rating and a $52.00 price objective for the company. Zacks Investment Research upgraded BeyondSpring from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of BeyondSpring in a research note on Monday, August 21st. Finally, Rodman & Renshaw upped their price objective on BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, July 14th.
BeyondSpring Inc. (BYSI) traded down 0.53% on Thursday, hitting $38.99. The stock had a trading volume of 11,960 shares. The firm’s market cap is $890.69 million. The firm’s 50-day moving average price is $38.03 and its 200-day moving average price is $34.21. BeyondSpring Inc. has a 1-year low of $16.55 and a 1-year high of $48.49.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.